Digital Desk, Jerusalem. A new study has found that the third vaccine dose of Pfizer-BioNtech proved more effective in reducing serious consequences related to Kovid-19 compared to individuals who had received two doses of the vaccine at least five months earlier.
The results showed that individuals who received three doses of the vaccine (7 days or more after the third dose) had a 92 percent lower risk of severe COVID-19 disease, compared to individuals who had received only two doses five months earlier. and 81 percent of the individuals had a low risk of death related to COVID-19. “These results clearly show that the third dose of the vaccine one week later is highly effective on severe COVID-19-related outcomes in different age groups and population subgroups,” said researcher Ran Balisar from Israel’s Clalit Research Institute.
These data, Balisar said, should facilitate informed policy decision-making. For the study, published in The Lancet journal, the team reviewed data from 7,28,321 individuals 12 or older who received a third dose of the 162B2 BNT vaccine. These individuals were carefully matched 1:1 to 7,28,321 individuals who had received only two shots of the 162B2 vaccine at least five months earlier.
The matching was based on a broad set of demographic, geographic and health-related characteristics associated with risk of infection, risk of serious illness, health status, and health-seeking behavior. Individuals were dynamically assigned to each group based on their changing vaccination status (1,98,476 individuals moved from an unvaccinated cohort to a vaccinated cohort during the study).